These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10544300)

  • 21. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relation between benign prostatic hyperplasia and obesity and estrogen].
    Matsuda T; Abe H; Suda K
    Rinsho Byori; 2004 Apr; 52(4):291-4. PubMed ID: 15164594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of estrogen supplementation on cell proliferation and expression of c-kit positive cells in the rat prostate.
    Kusljic S; Exintaris B
    Prostate; 2010 Oct; 70(14):1555-62. PubMed ID: 20687229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrastructural and biochemical expressions of divergent differentiation in prostates of castrated dogs treated with estrogen and androgen.
    Merk FB; Ofner P; Kwan PW; Leav I; Vena RL
    Lab Invest; 1982 Nov; 47(5):437-50. PubMed ID: 6182388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Physiopathological aspects of the treatment of benign prostatic hypertrophy. Role of prostatic stroma and estrogens].
    Solè-Balcells F
    J Urol (Paris); 1993; 99(6):303-6. PubMed ID: 7516373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estradiol causes the rapid accumulation of cAMP in human prostate.
    Nakhla AM; Khan MS; Romas NP; Rosner W
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5402-5. PubMed ID: 7515502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steroid hormones and the pathogenesis of benign prostatic hyperplasia.
    Griffiths K; Eaton CL; Harper ME; Peeling B; Davies P
    Eur Urol; 1991; 20 Suppl 1():68-77. PubMed ID: 1722166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prevention of benign prostatic hyperplasia (bph).
    Roper WG
    Med Hypotheses; 2017 Mar; 100():4-9. PubMed ID: 28236846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of sex steroid hormones in benign prostatic hyperplasia.
    Asiedu B; Anang Y; Nyarko A; Doku DA; Amoah BY; Santa S; Ngala RA; Asare GA
    Aging Male; 2017 Mar; 20(1):17-22. PubMed ID: 28084142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benign prostatic hyperplasia: pathogenesis and medical therapy.
    Geller J
    J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cigarette smoking: a review of possible associations with benign prostatic hyperplasia and prostate cancer.
    Matzkin H; Soloway MS
    Prostate; 1993; 22(4):277-90. PubMed ID: 7684523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4. Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate.
    Bartsch G; Daxenbichler G; Rohr HP
    J Steroid Biochem; 1983 Jul; 19(1A):147-54. PubMed ID: 6193337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen, estrogen, and progesterone receptors in normal and aging prostates.
    Srinivasan G; Campbell E; Bashirelahi N
    Microsc Res Tech; 1995 Mar; 30(4):293-304. PubMed ID: 7541676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia.
    Gleason PE; Jones JA; Regan JS; Salvas DB; Eble JN; Lamph WW; Vlahos CJ; Huang WL; Falcone JF; Hirsch KS
    J Urol; 1993 Jun; 149(6):1586-92. PubMed ID: 7684794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of tissue steroids in benign hyperplasia and prostate cancer].
    Voigt KD; Bartsch W
    Urologe A; 1987 Nov; 26(6):349-57. PubMed ID: 2448941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of androgen binding, androgen tissue levels, and sex hormone-binding globulin in prostate, muscle and plasma of patients with benign prostatic hypertrophy.
    Krieg M; Bartsch W; Herzer S; Becker H; Voigt KD
    Acta Endocrinol (Copenh); 1977 Sep; 86(1):200-15. PubMed ID: 71838
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of the stromal microenvironment in carcinogenesis of the prostate.
    Cunha GR; Hayward SW; Wang YZ; Ricke WA
    Int J Cancer; 2003 Oct; 107(1):1-10. PubMed ID: 12925950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
    Lau KM; LaSpina M; Long J; Ho SM
    Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etiological considerations for the growth of stroma in benign prostatic hyperplasia.
    Mawhinney MG
    Fed Proc; 1986 Oct; 45(11):2615-7. PubMed ID: 2428672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.